Tirzepatide Obesity Drug Shown to Reduce Body Weight by 20 Percent in Eli Lilly Trial
XTalks
APRIL 29, 2022
The promising trial results could pose a threat to Danish drugmaker Novo Nordisk’s GLP-1 agonist drug Wegovy (semaglutide), which has dominated the obesity drug market since its launch in 2021. Lilly’s Tirzepatide Takes on Novo Nordisk’s Semaglutide. Wegovy had a price tag of $1,297 a month when it was first launched.
Let's personalize your content